ArticleBiological psychiatry2013
A clinical risk stratification tool for predicting treatment resistance in major depressive disorder.
Article in Biological psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04234776 (Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression), which is not on this map. Cited by 78 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression
Who cites it
78 citing papers in PubMed, 7 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Machine learning in the prediction of treatment response for emotional disorders: A systematic review and meta-analysis.Clinical psychology review · 2025Pooled it
- Predicting treatment outcomes in major depressive disorder using brain magnetic resonance imaging: a meta-analysis.Molecular psychiatry · 2025Pooled it
- Pooled it
- Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice.Schizophrenia bulletin · 2021Pooled it
- The Impact of Alexithymia on Treatment Response in Psychiatric Disorders: A Systematic Review.Frontiers in psychiatry · 2020Pooled it
- Pooled it
- Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value.Journal of clinical psychopharmacologyPooled it
- A genetic risk score to predict treatment nonresponse in psychotic depression.Translational psychiatry · 2024Trial
- Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials.The international journal of neuropsychopharmacology · 2019Trial
- Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial.International clinical psychopharmacology · 2018Trial
- Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study.PloS one · 2018Trial
- Trial
- The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.BMC psychiatry · 2016Trial
- Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Pretreatment brain states identify likely nonresponse to standard treatments for depression.Biological psychiatry · 2014Trial
- Clinical predictors of ketamine response in treatment-resistant major depression.The Journal of clinical psychiatry · 2014Trial
- Impaired regional structure-function coupling as novel neurophenotype: mechanistic insights and diagnostic exploration in treatment-resistant depression.Npj mental health research · 2026Article
- Ingredients for Success: What Clients and Informal Caregivers Value in Depression Treatment A Concept Mapping Study.Journal of clinical psychology · 2026Article
- Who's at risk for emergent depression years later? Predictive modeling in a nine-year longitudinal cohort.BMC psychiatry · 2026Article
- Prediction of treatment-resistant depression using the 23andMe survey data.Scientific reports · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundEarly identification of depressed individuals at high risk for treatment resistance could be helpful in selecting optimal setting and intensity of care. At present, validated tools to facilitate this risk stratification are rarely used in psychiatric practice.
methodsData were drawn from the first two treatment levels of a multicenter antidepressant effectiveness study in major depressive disorder, the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) cohort. This cohort was divided into training, testing, and validation subsets. Only clinical or sociodemographic variables available by or readily amenable to self-report were considered. Multivariate models were developed to discriminate individuals reaching remission with a first or second pharmacological treatment trial from those not reaching remission despite two trials.
resultsA logistic regression model achieved an area under the receiver operating characteristic curve exceeding .71 in training, testing, and validation cohorts and maintained good calibration across cohorts. Performance of three alternative models with machine learning approaches--a naïve Bayes classifier and a support vector machine, and a random forest model--was less consistent. Similar performance was observed between more and less severe depression, men and women, and primary versus specialty care sites. A web-based calculator was developed that implements this tool and provides graphical estimates of risk.
conclusionRisk for treatment resistance among outpatients with major depressive disorder can be estimated with a simple model incorporating baseline sociodemographic and clinical features. Future studies should examine the performance of this model in other clinical populations and its utility in treatment selection or clinical trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.